drugset / Trial / NCT00478855

Tazocin Intervention Study

NCT00478855

Phase 4 Completed 500 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelPrevention

Summary

1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection. 2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.

Timeline

Start
2006-09
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Piperacillin Small molecule
Subject Tazobactem Unknown